Down syndrome regression disorder: updates and therapeutic advances.
Journal
Current opinion in psychiatry
ISSN: 1473-6578
Titre abrégé: Curr Opin Psychiatry
Pays: United States
ID NLM: 8809880
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
entrez:
27
1
2023
pubmed:
28
1
2023
medline:
31
1
2023
Statut:
ppublish
Résumé
Down syndrome regression disorder (DSRD) is a symptom cluster consisting of neuropsychiatric regression without cause. Although knowledge of this condition has accelerated over the last decade, prior studies have been limited by heterogenous nomenclature, diagnostic approaches and therapeutic interventions. This review highlights recent advances in the diagnosis and clinical approach to DSRD and reviews the most up-to-date literature on therapeutic interventions for this condition. Several multicentre studies have reported exciting findings on the presence of neurodiagnostic study abnormalities and responses to a variety of therapeutics, including psychotropics (including benzodiazepines), electroconvulsive therapy and immunotherapy. Differential response rates have been observed in the presence and absence of a variety of clinical and diagnostic factors. Individuals with DSRD are responsive to a variety of psychiatric pharmacotherapy and immunotherapy underscoring this phenotype may have multiple causes. Multidisciplinary care is helpful in the evaluation and management of individuals with this condition.
Identifiants
pubmed: 36705008
doi: 10.1097/YCO.0000000000000845
pii: 00001504-202303000-00003
doi:
Substances chimiques
Psychotropic Drugs
0
Benzodiazepines
12794-10-4
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
96-103Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Bull MJ. Down syndrome. N Engl J Med 2020; 382:2344–2352.
Rivelli A, Fitzpatrick V, Chaudhari S, et al. Prevalence of mental health conditions among 6078 individuals with Down syndrome in the United States. J Patient Cent Res Rev 2022; 9:58–63.
Tsou AY, Bulova P, Capone G, et al. Medical care of adults with Down syndrome: a clinical guideline. JAMA 2020; 324:1543–1556.
Santoro JD, Patel L, Kammeyer R, et al. Assessment and diagnosis of Down syndrome regression disorder: international expert consensus. Front Neurol 2022; 13:940175.
Rosso M, Fremion E, Santoro SL, et al. Down syndrome disintegrative disorder: a clinical regression syndrome of increasing importance. Pediatrics 2020; 145.
Worley G, Crissman BG, Cadogan E, et al. Down syndrome disintegrative disorder: new-onset autistic regression, dementia, and insomnia in older children and adolescents with Down syndrome. J Child Neurol 2015; 30:1147–1152.
Mircher C, Cieuta-Walti C, Marey I, et al. Acute regression in young people with Down syndrome. Brain Sci 2017; 7.
Santoro JD, Partridge R, Tanna R, et al. Evidence of neuroinflammation and immunotherapy responsiveness in individuals with down syndrome regression disorder. J Neurodev Disord 2022; 14:35.
Santoro SL, Baumer NT, Cornacchia M, et al. Unexplained regression in Down syndrome: management of 51 patients in an international patient database. Am J Med Genet A 2022; 188:3049–3062.
Jacobs J, Schwartz A, McDougle CJ, Skotko BG. Rapid clinical deterioration in an individual with Down syndrome. Am J Med Genet A 2016; 170:1899–1902.
Santoro SL, Cannon S, Capone G, et al. Unexplained regression in Down syndrome: 35 cases from an international Down syndrome database. Genet Med 2020; 22:767–776.
Walpert M, Zaman S, Holland A. A systematic review of unexplained early regression in adolescents and adults with Down syndrome. Brain Sci 2021; 11.
Stredny CM, Hauptman AJ, Sargado S, et al. Development of a multidisciplinary clinical approach for unexplained regression in Down syndrome. Am J Med Genet A 2022; 188:2509–2511.
Palumbo ML, McDougle CJ. Pharmacotherapy of Down syndrome. Expert Opin Pharmacother 2018; 19:1875–1889.
Thom RP, Palumbo ML, Thompson C, et al. Selective serotonin reuptake inhibitors for the treatment of depression in adults with Down syndrome: a preliminary retrospective chart review study. Brain Sci 2021; 11.
Miles JH, Takahashi N, Muckerman J, et al. Catatonia in Down syndrome: systematic approach to diagnosis, treatment and outcome assessment based on a case series of seven patients. Neuropsychiatr Dis Treat 2019; 15:2723–2741.
Ghaziuddin N, Nassiri A, Miles JH. Catatonia in Down syndrome; a treatable cause of regression. Neuropsychiatr Dis Treat 2015; 11:941–949.
Lyons A, Allen NM, Flanagan O, Cahalane D. Catatonia as a feature of down syndrome: an under-recognised entity? Eur J Paediatr Neurol 2020; 25:187–190.
Tamasaki A, Saito Y, Ueda R, et al. Effects of donepezil and serotonin reuptake inhibitor on acute regression during adolescence in Down syndrome. Brain Dev 2016; 38:113–117.
Johnson N, Fahey C, Chicoine B, et al. Effects of donepezil on cognitive functioning in Down syndrome. Am J Ment Retard 2003; 108:367–372.
Livingstone N, Hanratty J, McShane R, Macdonald G. Pharmacological interventions for cognitive decline in people with Down syndrome. Cochrane Database Syst Rev 2015; 2015:Cd011546.
Cardinale KM, Bocharnikov A, Hart SJ, et al. Immunotherapy in selected patients with Down syndrome disintegrative disorder. Dev Med Child Neurol 2019; 61:847–851.
Hart SJ, Worley G, Kishnani PS, Van Mater H. Case report: improvement following immunotherapy in an individual with seronegative Down syndrome disintegrative disorder. Front Neurol 2021; 12:621637.
Sargado S, Milliken AL, Hojlo MA, et al. Is developmental regression in Down syndrome linked to life stressors? J Dev Behav Pediatr 2022; 43:427–436.